OBJECTIVES: Systemic juvenile idiopathic arthritis (sJIA) is a childhood arthritis with features of autoinflammation and high risk of macrophage activation syndrome (MAS). IL-18 has been shown to have key roles in sJIA and MAS. We aimed to examine IL-18 levels in sJIA in relation to disease activity and history of MAS and other disease biomarkers namely S100 proteins and CXCL9. METHODS: Total IL-18, CXCL9 and S100 proteins levels were determined in 40 sJIA patients, and IL-18 levels were compared between patients with regards to disease activity, history of MAS, and other biomarkers. RESULTS: Total IL-18 levels were significantly higher in patients with active sJIA (median 16 499 pg/ml; interquartile range (IQR) 4816-61 839), and remained persistently elevated even in the majority of patients with inactive disease (1164 pg/ml; IQR 587-3444). Patients with history of MAS had significantly higher IL-18 levels (13 380 pg/ml; IQR 4212-62 628) as compared with those without MAS history (956.5 pg/ml; IQR 276.3-4262.5). Total IL-18 performed well with area under the curve of 0.8145 and 0.84 in predicting disease activity and history of MAS, respectively. We observed moderate correlation between IL-18 and CXCL9 (R = 0.56), S100A8/A9 (R = 0.47) and S100A12 (R = 0.46). The correlation was stronger for ferritin (R = 0.74) and overall for those with active disease. CONCLUSION: Total IL-18 levels were elevated in the majority of sJIA patients regardless of clinical features, but were higher in patients with active disease and history of MAS. Change in IL-18 may reflect increased disease activity or development of MAS.
OBJECTIVES: Systemic juvenile idiopathic arthritis (sJIA) is a childhood arthritis with features of autoinflammation and high risk of macrophage activation syndrome (MAS). IL-18 has been shown to have key roles in sJIA and MAS. We aimed to examine IL-18 levels in sJIA in relation to disease activity and history of MAS and other disease biomarkers namely S100 proteins and CXCL9. METHODS: Total IL-18, CXCL9 and S100 proteins levels were determined in 40 sJIA patients, and IL-18 levels were compared between patients with regards to disease activity, history of MAS, and other biomarkers. RESULTS: Total IL-18 levels were significantly higher in patients with active sJIA (median 16 499 pg/ml; interquartile range (IQR) 4816-61 839), and remained persistently elevated even in the majority of patients with inactive disease (1164 pg/ml; IQR 587-3444). Patients with history of MAS had significantly higher IL-18 levels (13 380 pg/ml; IQR 4212-62 628) as compared with those without MAS history (956.5 pg/ml; IQR 276.3-4262.5). Total IL-18 performed well with area under the curve of 0.8145 and 0.84 in predicting disease activity and history of MAS, respectively. We observed moderate correlation between IL-18 and CXCL9 (R = 0.56), S100A8/A9 (R = 0.47) and S100A12 (R = 0.46). The correlation was stronger for ferritin (R = 0.74) and overall for those with active disease. CONCLUSION: Total IL-18 levels were elevated in the majority of sJIA patients regardless of clinical features, but were higher in patients with active disease and history of MAS. Change in IL-18 may reflect increased disease activity or development of MAS.
Authors: Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo Journal: J Rheumatol Date: 2004-02 Impact factor: 4.666
Authors: Dirk Holzinger; Michael Frosch; Astrid Kastrup; Femke H M Prince; Marieke H Otten; Lisette W A Van Suijlekom-Smit; Rebecca ten Cate; Esther P A H Hoppenreijs; Sandra Hansmann; Halima Moncrieffe; Simona Ursu; Lucy R Wedderburn; Johannes Roth; Dirk Foell; Helmut Wittkowski Journal: Ann Rheum Dis Date: 2012-01-20 Impact factor: 19.103
Authors: Esi Morgan DeWitt; Yukiko Kimura; Timothy Beukelman; Peter A Nigrovic; Karen Onel; Sampath Prahalad; Rayfel Schneider; Matthew L Stoll; Sheila Angeles-Han; Diana Milojevic; Kenneth N Schikler; Richard K Vehe; Jennifer E Weiss; Pamela Weiss; Norman T Ilowite; Carol A Wallace Journal: Arthritis Care Res (Hoboken) Date: 2012-07 Impact factor: 4.794
Authors: Charlotte Girard; Jürgen Rech; Michael Brown; Danièle Allali; Pascale Roux-Lombard; François Spertini; Eduardo J Schiffrin; Georg Schett; Bernhard Manger; Sylvette Bas; Greg Del Val; Cem Gabay Journal: Rheumatology (Oxford) Date: 2016-09-10 Impact factor: 7.580
Authors: Marija Jelusić; Ivan Kresimir Lukić; Lana Tambić-Bukovac; Klara Dubravcić; Ivan Malcić; Igor Rudan; Drago Batinić Journal: Clin Rheumatol Date: 2006-11-25 Impact factor: 2.980
Authors: Paul Tsoukas; Emily Rapp; Lauren Van Der Kraak; Eric S Weiss; Vinh Dang; Corinne Schneider; Edwin Klein; Jennifer Picarsic; Rosalba Salcedo; C Andrew Stewart; Scott W Canna Journal: Blood Date: 2020-11-05 Impact factor: 22.113
Authors: D A B Rex; Nupur Agarwal; T S Keshava Prasad; Richard K Kandasamy; Yashwanth Subbannayya; Sneha M Pinto Journal: J Cell Commun Signal Date: 2019-12-20 Impact factor: 5.782
Authors: Scott W Canna; Grant S Schulert; Adriana de Jesus; Alex Pickering; Hermine Brunner; Massimo Gadina; Stewart Levine; Raphaela Goldbach-Mansky; Jonathan Boutelle; Rashmi Sinha; Fabrizio DeBenedetti; Alexei Grom Journal: Pediatr Rheumatol Online J Date: 2020-07-15 Impact factor: 3.054